Scholars@Duke

Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 Arg/Gly receptor polymorphism

Publication ,  Conference
White, M; Carson, P; Anand, IS; Gottlieb, SS; Lindenfeld, J; O'Connor, C; Miller, A; Plehn, J; Silver, MA; Fiuzat, M; Robertson, AD; Bristow, MR
Published in: CIRCULATION
October 16, 2007
Link to item

Duke Scholars

Mona Fiuzat
Author Mona Fiuzat Medicine, Clinical Pharmacology

Published In

CIRCULATION

ISSN

0009-7322

Publication Date

October 16, 2007

Volume

116

Issue

16

Start / End Page

176 / 176

Location

Orlando, FL

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Conference Name

80th Annual Scientific Session of the American-Heart-Association

Related Subject Headings

  • Cardiovascular System & Hematology
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
White, M., Carson, P., Anand, I. S., Gottlieb, S. S., Lindenfeld, J., O’Connor, C., … Bristow, M. R. (2007). Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 Arg/Gly receptor polymorphism. In CIRCULATION (Vol. 116, pp. 176–176). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS.
White, Michel, Peter Carson, Inder S. Anand, Stephen S. Gottlieb, JoAnn Lindenfeld, Christopher O’Connor, Alan Miller, et al. “Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 Arg/Gly receptor polymorphism.” In CIRCULATION, 116:176–176. LIPPINCOTT WILLIAMS & WILKINS, 2007.
White M, Carson P, Anand IS, Gottlieb SS, Lindenfeld J, O’Connor C, et al. Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 Arg/Gly receptor polymorphism. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 176–176.
White, Michel, et al. “Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 Arg/Gly receptor polymorphism.” CIRCULATION, vol. 116, no. 16, LIPPINCOTT WILLIAMS & WILKINS, 2007, pp. 176–176.
White M, Carson P, Anand IS, Gottlieb SS, Lindenfeld J, O’Connor C, Miller A, Plehn J, Silver MA, Fiuzat M, Robertson AD, Bristow MR. Effects of bucindolol on cardiovascular mortality and morbidity are determined by the beta-1 389 Arg/Gly receptor polymorphism. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 176–176.

Published In

CIRCULATION

ISSN

0009-7322

Publication Date

October 16, 2007

Volume

116

Issue

16

Start / End Page

176 / 176

Location

Orlando, FL

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Conference Name

80th Annual Scientific Session of the American-Heart-Association

Related Subject Headings

  • Cardiovascular System & Hematology
  • 4207 Sports science and exercise
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology